Cardioprotective effects of carvidolol and valsartan
|Full paper||Not Available|
Heart failure (HF) is a multifactorial and progressive disease that has been linked to activation of the renin-angiotensin and sympathetic systems. Carvedilol competitively blocks beta 1, beta 2 and alpha 1 receptors with potent antioxidant property, carvedilol has emerged as an effective treatment modality for heart failure. Nevertheless, the mechanism for improved cardiac function seen with f3-blocker treatment remains largely unknown. Valsartan is a potent and specific angiotensin II type I receptor antagonist that has been proven to be an effective antihypertensive drug. Valsartan has been claimed to posses prophylactic effect in cases of myocardial infarction and heart failure. In this study, cardioprotective effect of carvedilol (vasodilator beta adrenoreceptor blocker and valsartan (ARBs) were studied in model of heart failure induced by isoprenaline and in a model of acute myocardial infarction induced by isoprenaline. The main objective of the present study was to evaluate the cardioprotective effect of chronic carvedilol treatment, vasodilator non specific beta adrenoreceptor blocker versus valsartan specific angiotensin II type I receptor antagonist on arterial blood pressure, heart rate, infarct size assessed by triphenyltetrazolium chloride stain in heart failure induced experimentally by isopemaline in rats. The results of the present study showed that chronic carvedilol treatment (1mg/kg) and valsartan (3mg/kg) by gastric gavage for four weeks significantly decreased the arterial blood pressure and produced insignificant decrease in heart rate in heart failure induced experimentally by isoprenaline. And there was insignificant difference between both drugs on blood pressure lowering effects or change in heart rate.